Expertise

genmedics directly exploits research results that can be used for the development of therapeutic compounds in the Life Science Industry. We provide exceptional resources and expertise in applied gene technology including:

• Development and manufacturing of anti-infectives for life science companies and veterinary medicines
• Expression and purification of plasmid DNA, recombinant DNA derived peptides and proteins for industrial and therapeutic applications
• Custom-made research tools, bioactivity assay development and high throughput screening
• Detection and quantification of targets for biofilm formation on medical and industrial materials
• Detection and quantification of pathogenicity factors and resistance markers of staphylococci
• Optimization of host strains
• Optimization of food-grade staphylococcal strains
• Production of heterologuous proteins and industrial enzymes using the food-grade Staphylococcus carnosus

A major focus is the search for and the development and production of new anti-infectives against multiply resistant Gram-positive bacteria such as Methicillin- or Vancomycin-resistant Staphylococcus aureus (MRSA or VRSA), Vancomycin-resistant enterococci (VRE) and clostridia. In this respect genmedic’s lead peptide is the patented Gallidermin. In order to detect further anti-infective lead substances, potential drug targets are identified in pathogenic bacteria and promising drug candidates are screened.

genmedics accesses a high-level expression system for the production of heterologuous proteins via a genetically engineered strain of the food-grade Staphylococcus carnosus. This expression system enables the company to produce large amounts of proteins in a protease-deficient, Gram-positive and endotoxin-free bacterial strain. As a service, genmedics offers the ability to clone and express a gene of interest and to purify the corresponding gene product including analytical characterization. genmedics has, over the years, developed an expertise in producing various enzymes, hormones and plasmids in the food-grade bacterium Staphylococcus carnosus correctly folded and secreted to the medium.

Biofilm formation is a fundamental process in the life cycle of major medically and industrially important microorganisms and is commonly recognized as an increasing problem. Typically these microorganisms produce slime (an extracellular polysaccharide) contributing to the formation of a confluent biofilm that protects the embedded staphylococci against host response mechanisms and antibiotics. As a consequence, inhibition of biofilm formation represents one of the greatest challenges in fighting chronic polymer-associated infections. genmedics is able to perform assays for biofilm formation or drug discovery on the basis of the expression of improved light-emitting reporter systems in various staphylococci. genmedics screens and develops inhibitors of biofilm formation by means of these assays. We can also analyze new medical materials for biofilm-forming propensity or screen compound libraries for biofilm-inhibiting activity.

genmedics holds a number of patents including those for potential drug targets as well as others for promising drug candidates that are currently under investigation.